Physician profile
Jane B Sofair
NPI 1811946494
$734.23
in general payments reported to CMS, 2019-2025
10 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2023: $176 · 2024: $95.58 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $145.55 | 2019 | |
| Neurocrine Biosciences, INC. | $137.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $131.37 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $93.95 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $84.26 | 2019-2024 | Invega Trinza, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $65.97 | 2025 | Cobenfy |
| Allergan, INC. | $24.43 | 2019 | |
| Abbvie INC. | $20.31 | 2025 | |
| Lundbeck LLC | $17.00 | 2023 | Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Sofair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.